Hennion & Walsh Asset Management Inc. trimmed its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 12.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 420,211 shares of the company’s stock after selling 61,274 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.48% of Olema Pharmaceuticals worth $5,257,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC increased its position in Olema Pharmaceuticals by 24.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after acquiring an additional 1,664,687 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in shares of Olema Pharmaceuticals by 11.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock worth $188,604,000 after purchasing an additional 750,000 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Olema Pharmaceuticals by 5.9% during the first quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock worth $106,013,000 after purchasing an additional 398,294 shares in the last quarter. Siren L.L.C. lifted its position in shares of Olema Pharmaceuticals by 44.1% during the first quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock worth $70,926,000 after purchasing an additional 1,456,249 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Olema Pharmaceuticals by 11.4% during the fourth quarter. Vanguard Group Inc. now owns 3,561,355 shares of the company’s stock valued at $89,034,000 after purchasing an additional 364,035 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.
Olema Pharmaceuticals Price Performance
Shares of NASDAQ OLMA opened at $12.05 on Monday. Olema Pharmaceuticals, Inc. has a 1 year low of $4.47 and a 1 year high of $36.26. The firm’s 50-day moving average is $11.26 and its 200-day moving average is $15.87. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.05 billion, a PE ratio of -5.97 and a beta of 2.03.
Insider Activity at Olema Pharmaceuticals
In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the sale, the director owned 715,270 shares in the company, valued at approximately $8,282,826.60. The trade was a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 12.56% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently weighed in on OLMA. HC Wainwright reissued a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Wall Street Zen downgraded Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. Weiss Ratings lowered Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 3rd. Finally, Guggenheim lowered their target price on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.10.
Get Our Latest Stock Analysis on OLMA
About Olema Pharmaceuticals
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Articles
- Five stocks we like better than Olema Pharmaceuticals
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
